Equities research analysts at Lazard Capital Markets upped their price target on shares of Celgene (NASDAQ: CELG) from $123.00 to $128.00 in a research note issued to investors on Thursday. The firm currently has a “buy” rating on the stock.

CELG has been the subject of a number of other recent research reports. Analysts at BMO Capital Markets reiterated an “outperform” rating on shares of Celgene in a research note to investors on Monday. They now have a $113.00 price target on the stock. Separately, analysts at Cantor Fitzgerald raised their price target on shares of Celgene from $115.00 to $121.00 in a research note to investors on Monday. They now have a “buy” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Celgene in a research note to investors on Thursday, February 28th. They now have a $106.00 price target on the stock.

Twenty-two research analysts have rated the stock with a buy rating, three have issued an overweight rating, and seven have issued a hold rating to the company. The stock has a consensus rating of “overweight” and a consensus price target of $113.01.

Celgene traded up 0.14% on Thursday, hitting $110.18. Celgene has a 1-year low of $58.53 and a 1-year high of $110.80. The stock’s 50-day moving average is currently $100.4. The company has a market cap of $46.137 billion and a price-to-earnings ratio of 33.34.

Celgene last issued its quarterly earnings data on Thursday, January 24th. The company reported $1.32 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.31 by $0.01. The company had revenue of $1.42 billion for the quarter, compared to the consensus estimate of $1.45 billion. During the same quarter last year, the company posted $1.05 earnings per share. Celgene’s revenue was up 14.0% compared to the same quarter last year. Celgene has set its FY13 guidance at $5.50-5.60 EPS. On average, analysts predict that Celgene will post $5.67 earnings per share for the current fiscal year.

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.